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Abstract
Purpose of review—We review the current state of evidence-based prevention strategies for
reducing sexual transmission of HIV. The combined programmatic and scientific efforts through
2008 to reduce sexual transmission of HIV have failed to reduce substantially the global
pandemic.
Recent findings—Prevention interventions to reduce HIV infection target behavioral,
biomedical, and structural risk factors. Some of these prevention strategies have been evaluated in
randomized clinical trials (RCTs) with HIV seroincidence endpoints. When RCTs are not feasible,
a variety of observational and quasiexperimental research approaches can provide insight as to
program effectiveness of specific strategies. Only five RCTs have demonstrated a notable decrease
in sexually acquired HIV incidence. These include the Mwanza study of syndromic management
of sexually transmitted diseases and three male circumcision trials in East Africa; a microbicide
trial reported in 2009 shows substantial promise for the efficacy of PRO 2000 (0.5% gel).
Summary—The combined programmatic and scientific efforts to reduce sexual transmission of
HIV have made incremental progress. New prevention tools are needed to stem the continued
spread of HIV, though microbicides and vaccines will take many more years to develop, test, and
deploy. Combination strategies of existing modalities should be tested to evaluate the potential for
more proximate prevention benefits.
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Introduction
The spread of the human immunodeficiency virus (HIV) represents the worst global
pandemic since the bubonic plague in 14th century Europe and Asia. Between 1981 and
2007, 64.9 million people are estimated to have been infected with HIV of whom about half
have died [1]. In 2007 alone, 2.5 million persons were infected with HIV –90% of whom
Correspondence to Sten H. Vermund, MD, PhD, Vanderbilt Institute for Global Health, 2215 Garland Drive (319 Light Hall),
Nashville, TN 37232-0242, USA, Tel: +1 615 322 9374; fax: +1 615 322 9400; sten.vermund@vanderbilt.edu.
NIH Public Access
Author Manuscript
Curr Opin HIV AIDS. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:













live in Sub-Saharan Africa, Asia, and Eastern Europe [2]. About 80% of all newly infected
persons acquired infection through sexual contact [3,4]. The combined programmatic and
scientific efforts to reduce sexual transmission of HIV have failed to address the pandemic
effectively.
Diversity in how the epidemic manifests itself is a key challenge. The virus has considerable
genetic variability, inhibiting the development of an effective HIV vaccine. The diversity of
infected populations reflects the diverse modes of transmission – heterosexual, homosexual,
needle-related, blood and blood product-related, and perinatal. Diversity in the route of
transmission and in the burden of disease presents a mosaic of dynamic subepidemics, each
driven by a variety of behavioral, structural and biological risk factors. In this review, we
emphasize evidence-based prevention efforts targeting sexual transmission, particularly
those published in 2007 and 2008.
HIV prevention: a failure of implementation
A failure of vision and/or political commitment to implement what we know works has
limited the success of HIV-prevention efforts. UNAIDS estimated that in 2005, fewer than
one in five people could access any known HIV-prevention strategies [5]. When prevention
interventions are accessible and coupled with behavioral changes substantial decreased in
HIV incidence can occur. The ‘ABC’ of delaying sexual debut in youth (abstinence),
reducing the number of sexual partners and reducing concurrent sexual relationships (be
faithful), and correct, consistent condom use reduced HIV seroincidence in Uganda,
Thailand, and perhaps elsewhere [6–10]. As background HIV prevalence rises within
populations, there is a poor correlation between personal risk factors and probability of HIV
acquisition. The probability of exposure per sexual encounter, related to background
prevalence, becomes the single biggest risk factor for getting infected in generalized
epidemics and within at-risk subgroups.
This epidemic has been further exacerbated by ignoring the complex array of societal and
contextual factors that increase a person’s risk for HIV infection. Focusing exclusively on
individual and personal risk factors and dependence on intrinsically driven behaviors will
not adequately address current epidemic trajectories. Community stigma inhibits community
education, testing for HIV, and access to prevention and care. Sex and power dynamics
including survival strategies and economic pressures are critical extrinsic factors that
diminish individual autonomy and control of HIV-risk reduction. To reduce sexual risk
inherently requires, at a minimum, engaging the sexual dyad, whether heterosexual or
homosexual. Exclusion of women from the formal economy, as well as societal expectations
of subservience and procreation fuel vulnerability of women through the adoption of a
variety of survival strategies. This vulnerability can manifest in sex work to feed one’s
children, sexual liaisons to enable school continuation, remaining in abusive marital
relations, sexual exploitation in the work-place, forced marriage, and exposure to life-
threatening HIV/AIDS stigma [11–14]. These are best described in Africa and Asia, but may
apply anywhere in the world.
Preventing HIV infection: randomized controlled trials
Observational studies have generated a substantial body of literature on a range of
biomedical, behavioral, and structural interventions associated with lowered HIV-risk
behaviors and/or HIV incidence [15–17]. However, prevention interventions have only
rarely proved efficacious when tested in randomized clinical trials (RCTs) with HIV
endpoints. Furthermore, there has been a poor correlation between behavior change and
reduction in HIV-incidence rates. Between 2005 and 2007, several important, innovative
Phase III HIV prevention RCTs were in progress (Table 1) [18–39].
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By 2007, as the trials reached completion or were stopped early for reasons of harm or
futility, negative sentiments about HIV prevention science started to emerge. This situation
was most notable in the vaccine and microbicide fields. Just months after a 2008 Science
[40] article that discussed some of the current failures in the microbicide field and
questioned the future of the microbicides, a promising microbicide result for PRO 2000
(0.5%) gel (discussed later) was presented at the 16th Conference on Retroviruses and
Opportunistic Infections [41•]. This good news notwithstanding, most recent prevention
trials (with the important exception of the male circumcision trials) have not demonstrated
efficacy in preventing HIV infection [27••,29,30,33,42].
The number of recently completed but unsuccessful prevention trials mask important
progress in the efforts to reduce HIV infection. Building on observations in couples from
Quinn et al. [43] and Fideli et al. [44] on the close correlation between viral load and HIV
transmission, new opportunities for HIV prevention have emerged through expanding access
to testing and knowledge of HIV status, linked to antiretroviral therapy (ART) for infected
persons. This ‘test and treat’ concept has potential as an intervention for decreasing viral
load in communities and thus reducing the probability of transmission at a population level.
The use of ART as a prevention tool has already proven effective in prevention of mother-
to-child HIV transmission (PMTCT) – women who are given ART during pregnancy and
postpartum have a significantly decreased risk for transmission of virus to their newborn
[45–47]. However, use of ART, as a prevention tool requires patients to know their HIV-
positive status, have access to care, and to adhere to medications necessary to lower viral
loads and minimize antiviral drug resistance. With six drug classes now in use
(http://www.fda.gov/oashi/aids/virals.html, accessed 30 March 2009), several of which are
in affordable generic formulations, advances in the field of antiviral chemotherapy have
made effective viral load reduction even more feasible.
Vaccines
The ‘Step’ study of the MRK Ad5 gag/pol/nef HIV-1 vaccine did not indicate vaccine
benefit in adenovirus-seronegative persons and showed higher HIV serocon-version in
adenovirus-seropositive persons [37••]. Deep tissue HIV invasion may occur in just 2 weeks
or less, demonstrating how hard it will be to use a human immunologic barrier to block HIV,
given the current state of knowledge [48].
Physical barriers
Although the effectiveness of male condoms is exceedingly well documented despite the
lack of a RCT [49], condom usage rates are still low in most high-risk persons globally. The
Zimbabwean MIRA trial did not suggest the female diaphragm to be more successful in
preventing HIV compared with condom use alone [31]. Efficacy of female condoms remains
unknown and unstudied in clinical trials; effectiveness data are also sparse.
Chemical barriers (topical microbicides)
Cellulose sulfate gel, 1.0% C31G (SAVVY), Carraguard, and Buffer-gel products failed to
prevent HIV transmission in prevention RCTs [32–36,41•,50]. However, PRO 2000 (0.5%)
gel, a nonspecific entry/fusion inhibitor, was 30% effective (0.05 <P ≤ 0.10 against placebo
gel or no gel groups, P <0.05 against placebo and no gel groups combined) in reducing HIV
incidence [41•]. Microbicide trials with antiretroviral active agents (e.g., tenofovir) are in
progress [51].
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Oral prophylactic antiretroviral therapy
Animal data suggest that ART can be given before HIV exposure and continued for several
weeks after exposure to reduce risk of HIV transmission [52–55]. Preexposure prophylaxis
(PrEP), some with postexposure (PEP) components are in progress worldwide in both men
who have sex with men (MSM) and at-risk heterosexuals. Perhaps the most promising
product (as of this 2009 writing) is tenofovir combined with emtricitabine (TDF/FTC or
Truvada) due to its lower likelihood of emerging drug resistance, high genital tract
concentrations, and long half-life [56,57]. If effective, implementation will be challenging,
especially in more resource-limited settings where even HIV-infected persons are
underserved with antiretroviral services. Nonetheless, if drug prices fall, decision analysis
models suggest it could be a cost-effective intervention [58].
Male circumcision
Randomized clinical trials in South Africa, Uganda, and Kenya demonstrated approximately
50% seroincidence decline in circumcised heterosexual men [23–25]. This has galvanized an
effort to expand such services in high prevalence venues, given their high cost efficiency
[59–61]. As scale-up occurs, mitigation of harm from suboptimal surgery will be a challenge
[62–64]. Benefits of circumcision to MSM are unknown, and would only be expected to
benefit men who are exclusively (or almost exclusively) insertive in their sexual acts
[65,66].
Control of sexually transmitted infections
The suppression of herpes simplex virus type-2 infection with chronic acyclovir did not
reduce HIV seroconversions in either MSM in the Americas or with high-risk heterosexual
women in Africa [21••,22•]. This was disappointing given the very strong correlation of
HSV-2 infection with risk of HIV acquisition reported in observational studies; many in the
field expected HSV-2 suppression to mimic adult male circumcision successes [67]. In
addition to these more recent trials, previous community-RCTs have examined the effect of
improved STI treatment on HIV transmission [18–20,26]. The results of these studies were
mixed suggesting that treatment of bacterial STI may be more effective in preventing HIV
infection in settings with low-to-emerging HIV epidemics or mature epidemics with high
incidence and where there is a high background prevalence of bacterial STI [68–71].
Behavior change and youth
Work is in progress on an array of approaches and strategies [15]. A meta-analysis
suggested no efficacy of abstinence-only-based behavior change in preventing HIV, but
promise was shown for more comprehensive ‘abstinence-plus’ programs [72–74]. A
community RCT in Tanzania did not demonstrate reduced HIV incidence in adolescent girls,
despite improving knowledge, attitudes, and reducing some sexual risk behaviors in boys
[42]. The Stepping Stones initiative in rural South Africa was a behavioral intervention that
did not reduce incidence of HIV in 15–26 year olds, but had a significant impact on reducing
HSV-2 incidence and intimate partner violence [27••]. However, this study did not
demonstrate a change in HIV rates, reinforcing that there are no good surrogate markers for
HIV incidence itself [27••]. A RCT of risk reduction among Zimbabwean adolescents is in
progress, having recruited a very high proportion of youth into the intervention vs. control
groups before they became sexually active [29].
Structural intervention
Structural interventions are policy changes that encourage risk reduction. Raising cigarette
taxes to discourage youth from smoking and banning smoking in public indoors areas are
two familiar examples. The Microfinance for AIDS and Gender Equity (IMAGE) study
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combined a microfinance program with training in sex–power relationships and HIV-risk
reduction in rural South Africa. Reductions in levels of intimate-partner violence were
significant in the intervention arm along with reductions in HIV-risk behaviors [75], but
HIV rates did not differ [30]. Although HIV results were disappointing, the RCT illustrates
how multi-component interventions will be used to try to break the cycle of HIV
transmission.
In summary, 28 years into the pandemic only five randomized controlled trials have
demonstrated a decrease in HIV-incidence rates. The Mwanza trial demonstrated a 42%
reduction in HIV seroincidence in persons living in communities with immediate availability
of syndromic management of bacterial sexually transmitted diseases (STDs) [20]. This
promising finding was not observed in the context of three subsequent phase III RCTS of
STD intervention studies in the Rakai, Masaka, Manicaland regions [18,19,26]. A
microbicide has shown promise in the HPTN035 study of PRO 2000 0.5% gel [41•]. The
protective effect of medical male circumcision in preventing female–male transmission of
HIV has been confirmed consistently in three independently conducted phase III RCTs [23–
25]. The translation of these impressive finding has been limited by political, cultural/social
and programmatic challenges [59,61,62,76–81]. This leaves us with a limited arsenal of
proven HIV-prevention strategies, though circumstantial evidence of male condom efficacy
and salutary benefits of delayed sexual debut and partner reduction remain compelling.
Methodological challenges
Notwithstanding the scientific challenges in preventing HIV infection, the conduct of RCTs
in HIV prevention has numerous additional challenges in design, selecting appropriate
outcome measures for both efficacy and effectiveness studies including the lack of proxy
markers for protection [82•,83]. A key factor contributing to small effect size of
interventions is the ethical obligation to provide risk reduction education in comparison or
control populations, even in settings where there remains limited access to prevention in the
real world. For example in the MIRA RCT, female diaphragms and condoms were
compared against condoms alone [31]. Although women using diaphragms had the same
transmission rates as those whose partners used condoms, it was interpreted widely that
diaphragms were ineffective. A more correct interpretation was that they might have been
equally efficacious as condoms, as condom use in the diaphragm group was uncommon,
despite encouragements for their use.
The prevention community has also been slow to embrace combination prevention efficacy
trials despite what we have learned from therapeutic trials or strategies in the PMTCT field
about the importance of using more comprehensive intervention strategies targeting all
potential routes of viral entry and/or replication. Instead, HIV-prevention efforts have
adopted the approach of incremental/attributable risk reduction. Although these unitary
strategies for HIV prevention are alluring in theory (lower cost, ease of implementation);
research investments (from the USA National Institute of Allergy and Infectious Diseases,
the United Kingdom Medical Research Council, and the Bill and Melinda Gates Foundation,
for example) have disproportionately emphasized ‘magic bullets’ for HIV prevention (i.e.,
prophylactic vaccines, PrEP, and microbicides) compared with more complex
multicomponent interventions. The latter could have epidemic impact of more immediacy
and effectiveness [37••,40,84]. The authors of this review believe that future trials must
combine interventions, each with small effects but with the potential for synergy if
combined. Prevention science strategies and trial conduct needs to take into account the
myriad of biological, behavioral, and structural factors that increase a person’s risk for
infection at multiple levels. Rarely does an individual at risk of getting infected with HIV
have a single intrinsic factor that might lead to infection.
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A diverse biomedical and biobehavioral portfolio of research is essential for us to make
progress in HIV control. Building on the tools provided by basic, clinical, and social
sciences, we need to move new products and strategies into rigorous field testing.
Implementation of single modality interventions will not solve the problem. History has
taught us through PEPFAR and the Global Fund to Fight AIDS, tuberculosis and malaria
that ‘where there is a will there is a way’. These therapeutic implementation successes have
also highlighted the numerous challenges in the context of failing healthcare delivery
systems, inadequate infrastructure and limited human resources to attain access, coverage
and acceptability levels needed to make a difference to current epidemic trajectories
[85,86,87•].
Vaccines and microbicides are still seen as the holy grails of prevention as reflected in
budgetary allocations. Although these approaches will remain an important part of our
medium-to long-term strategy, we must invest in strategies with impact in the shorter term.
Combinations of interventions based on existing tools such as the delaying sexual debut,
partner fidelity, use of condom barriers (the abstinence, be faithful, correct condom use
‘ABC’ mantra), and male circumcision will be needed to complement whatever biomedical
interventions are made available and are used by the target communities. We believe that the
lessons learned suggest that multicomponent, multilevel interventions with careful
monitoring and evaluation in implementation will be more likely to succeed than unitary
biomedical approaches.
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